Cancer, Malaria & TB Vaccines
Malaria continues to claim an estimated 2 to 3 million lives annually and to account for untold morbidity in the approximately 300 to 500 million people infected annually. Malaria is considered a re-emerging disease, due largely to the spread of drug-resistant parasite strains, decay of health-care infrastructure and difficulties in implementing and maintaining vector control programs in many developing countries. Four species of protozoan parasites cause malaria in humans: Plasmodium falciparum, P. vivax, P. malariae, and P. ovale. P. falciparum is responsible for the majority of deaths and most of the severe forms of disease, including cerebral malaria. 2 billion people latently infected with M. tuberculosis 5-10% infected people progress to disease 9 million new TB cases each year 1.5 million TB deaths each year Equivalent to 20 passenger aircraft crashes each day. TB is transmitted by adults with cavitatory disease HIV infected people carry greater burden of disease. Highest risk of progression from TB infection to active disease, and worst TB morbidity and mortality, compared to older children and adults.
Related Conference of Cancer, Malaria & TB Vaccines
21th International Conference on Allergic Diseases and Clinical Immunology
13th World Congress and Exhibition on Antibiotics and Antibiotic Resistance
Cancer, Malaria & TB Vaccines Conference Speakers
Recommended Sessions
- Animal & Plant Derived Vaccines
- Animal Models & Clinical Trials
- Antibodies: Engineering & Therapeutics
- Cancer, Malaria & TB Vaccines
- Cellular Immunology & Latest Innovations
- Combination & Conjugate Vaccines
- Current Research & Future Challenges
- DNA & Synthetic Vaccines
- Fish & Poultry Vaccines
- Geriatric Immunization
- HIV Vaccines
- Paediatric Vaccination
- Travel & Edible Vaccines
- Vaccine Production & Development
- Vaccine Safety & Efficacy
- Vaccines & Autism
- Vaccines against Drugs‎
- Vaccines against Infectious Diseases
- Vaccines for Immune Mediated Diseases
- Vaccines for Pregnant Women & Neonates
- Vaccines for Unconventional Diseases
- Vectors, Adjuvants & Delivery Systems
Related Journals
Are you interested in
- Adaptive Immunity, Memory Formation & T-Cell Engineering - European Immunology 2026 (France)
- Allergy, Hypersensitivity & Immune Tolerance - Immunology 2026 (France)
- Allergy, Hypersensitivity & Immune Tolerance Strategies - European Immunology 2026 (France)
- Antibiotic Prophylaxis - Antibiotics 2026 (UK)
- Antibiotic Resistance: Opportunities and Challenges - Antibiotics 2026 (UK)
- Antibiotic-resistant Bacterial infections - Antibiotics 2026 (UK)
- Antibiotics - Antibiotics 2026 (UK)
- Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- Antibiotics: In Pregnancy and Lactation - Antibiotics 2026 (UK)
- Antimicrobial Peptides - Antibiotics 2026 (UK)
- Antimicrobial Therapy - Antibiotics 2026 (UK)
- Autoimmune & Inflammatory Disorders - Immunology 2026 (France)
- Autoimmunity Mechanisms & Precision Immunoregulation - European Immunology 2026 (France)
- Cancer Immunology & Tumor Microenvironment - Immunology 2026 (France)
- Cellular Signaling & Cell Fate Determination - Immunology 2026 (France)
- Clinical and Translational Immunology - Immunology 2026 (France)
- Clinical Trials of Antibiotics - Antibiotics 2026 (UK)
- Computational Immunology, AI Modeling & Immune System Simulation - European Immunology 2026 (France)
- Current Research in Antibiotic Resistance - Antibiotics 2026 (UK)
- Cytokine Signaling Networks & Immune Modulation - European Immunology 2026 (France)
- Developing Alternatives to Antibiotics - Antibiotics 2026 (UK)
- Drug Discovery and Novel Delivery Technologies - Antibiotics 2026 (UK)
- Immune Cell Reprogramming & Gene-Edited Immunotherapies - European Immunology 2026 (France)
- Immunogenetics & Epigenetic Regulation - Immunology 2026 (France)
- Immunology & Vaccines - Antibiotics 2026 (UK)
- Immunometabolism - Immunology 2026 (France)
- Immunometabolism & Cellular Energy Dynamics - European Immunology 2026 (France)
- Immunotherapy & Immune Modulation - Immunology 2026 (France)
- Infectious Diseases - Antibiotics 2026 (UK)
- Infectious Diseases & Host–Pathogen Interactions - Immunology 2026 (France)
- Inflammation Biology & Chronic Immune Disorders - European Immunology 2026 (France)
- Innate and Adaptive Immune Mechanisms - Immunology 2026 (France)
- Innate Immune Sensors, Pattern Recognition & Host Defense - European Immunology 2026 (France)
- Innovations in Cell Biology & Imaging Technologies - Immunology 2026 (France)
- Mechanisms and Evolution of Antibiotic Resistance - Antibiotics 2026 (UK)
- Micro Organisms in Recent Drug Discovery - Antibiotics 2026 (UK)
- Microbiome–Immune Axis & Host Interaction Pathways - European Immunology 2026 (France)
- Microorganisms Producing Antibiotics - Antibiotics 2026 (UK)
- Modern Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- Molecular & Cellular Immunology - Immunology 2026 (France)
- Mucosal Immunity & Barrier Protection Mechanisms - European Immunology 2026 (France)
- Nanotechnology-Enabled Immune Delivery Systems - European Immunology 2026 (France)
- Neuroimmunology & Brain–Immune Interactions - Immunology 2026 (France)
- New antibiotics and non-antibiotic approaches - Antibiotics 2026 (UK)
- Next-Generation Vaccines & Antigen Engineering - European Immunology 2026 (France)
- Pharmacokinetics and Pharmacodynamics of Antimicrobial Drugs - Antibiotics 2026 (UK)
- Pharmacology & Toxicology - Antibiotics 2026 (UK)
- Prevention and Control of Antibiotic Resistance - Antibiotics 2026 (UK)
- Stem Cells & Regenerative Immunology - Immunology 2026 (France)
- The Next Generation Approach of Antibiotics - Antibiotics 2026 (UK)
- Tumor Immunology & Personalized Cancer Immunotherapies - European Immunology 2026 (France)
- Vaccines & Vaccine Technology - Immunology 2026 (France)
- Viral Immunology, Emerging Pathogens & Host Response - European Immunology 2026 (France)
